Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
An erratum to this article was published (Eur Heart J, 14 Jul 2023 ↗)
Recommendations
As issued by the authors
Renal denervation (RDN) is an adjunct treatment option in uncontrolled resistant hypertension, confirmed by ambulatory blood pressure (BP) measurements, despite best efforts at lifestyle and pharmacological interventions.
RDN may also be used in patients unable to tolerate antihypertensive medications in the long term.
Shared decision-making is a key feature, preferably with a patient well informed on the benefits and limitations of the procedure.
Decision-making should take into account the patient's global cardiovascular (CV) risk and/or hypertension-mediated organ damage or CV complications.
Multidisciplinary hypertension teams of hypertension experts and interventionalists evaluate the indication and facilitate the RDN procedure.
Interventionalists require expertise in renal interventions and specific training in RDN procedures.
Centres performing RDN require the skills and resources to deal with potential complications.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →